Why the study?
Does the EXCOR Pediatric VAD improve survival time compared to extracorporeal membrane oxygenation in pediatric patients as a bridge to transplant?
Does the EXCOR Pediatric VAD improve survival time compared to extracorporeal membrane oxygenation in pediatric patients as a bridge to transplant?
The EXCOR Pediatric VAD demonstrated significant survival benefit relative to ECMO as a bridge to transplant in children.
EXCOR VAD shows longer median survival than ECMO as pediatric bridge to transplant; leaves open need for updated comparative data.
The only pediatric left ventricular assist device (pLVAD) specifically approved for use in children by the Food and Drug Administration is the EXCOR Pediatric VAD (Berlin Heart GmbH, Berlin, Germany). The EXCOR VAD gained approval on the basis of a clinical study in 2012 demonstrating significant survival benefit relative to extracorporeal membrane oxygenation in patents receiving it as a bridge to transplant.1 The median survival time was longer than 144 days for the pLVAD, whereas it was only 10 days in the matched extracorporeal membrane oxygenation cohort.
No takes yet. Share an insight, caveat, or question.
Leslie et al. (2017) conducted a review in Heart failure requiring bridge to transplant in children. EXCOR Pediatric VAD vs. Extracorporeal membrane oxygenation was evaluated on Median survival time (days).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: